Traditional drug discovery is expensive, inefficient, and has huge barriers to entry. Big pharmaceutical companies continue to struggle to cope with tight margins…

This is the third in a three-part series by Dr. Heather Buschman on Big Data in the pharmaceutical and biotechnology industries. Check out…

The need for CNS therapeutics is on the rise.  Neurological diseases are expected to increase steadily in the coming years.  Previously, we addressed…

Use of CROs in research and drug development in increasing.  ADDF shared their recommendations for navigating CRO selection 1.  We’ve summarized their insights…

Contract research organizations (CROs) often have experience overseeing all aspects of a drug development program.  ADDF recently shared their insights on navigating CRO…